nach oben

Journal of Interventional Cardiac Electrophysiology

Erschienen in:

25.07.2020 | Commentary

Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists

verfasst von: Arya Aminorroaya, Ali Vasheghani-Farahani, Farzad Masoudkabir, Pegah Roayaei

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Sudden cardiac death (SCD) related to ventricular arrhythmias is the most disastrous consequence of hypertrophic cardiomyopathy (HCM). Hence, clinicians seek to identify the highest risk patients that have the greatest potential to benefit from an implantable cardioverter-defibrillator (ICD) for primary prevention; nonetheless, this is where controversies begin as the 2011 American College of Cardiology Foundation/American Heart Association and the 2014 European Society of Cardiology guidelines have significant discrepancies. These guidelines propose clinically and statistically oriented algorithms, respectively, for SCD risk stratification of patients with HCM and recommendation to implantation of primary prevention ICD. The differences between these guidelines have resulted in confusion among care practitioners and patients alike. In this communication, we tried to criticize the statistical viewpoint in terms of clinical outcomes and suggest the more beneficial model.

Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2011;142(6):e153–203. https://doi.org/10.1016/j.jtcvs.2011.10.020.CrossRefPubMed

Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79. https://doi.org/10.1093/eurheartj/ehu284.CrossRefPubMed

Ruiz-Salas A, Garcia-Pinilla JM, Cabrera-Bueno F, Fernandez-Pastor J, Pena-Hernandez J, Medina-Palomo C, et al. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator. Europace. 2016;18(5):773–7. https://doi.org/10.1093/europace/euv079.CrossRefPubMed

Vriesendorp PA, Schinkel AF, Liebregts M, Theuns DA, van Cleemput J, Ten Cate FJ, et al. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8(4):829–35. https://doi.org/10.1161/CIRCEP.114.002553.CrossRefPubMed

Fernandez A, Quiroga A, Ochoa JP, Mysuta M, Casabe JH, Biagetti M, et al. Validation of the 2014 European Society of Cardiology sudden cardiac death risk prediction model in hypertrophic cardiomyopathy in a reference center in South America. Am J Cardiol. 2016;118(1):121–6. https://doi.org/10.1016/j.amjcard.2016.04.021.CrossRefPubMed

O'Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, et al. International external validation study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation. 2018;137(10):1015–23. https://doi.org/10.1161/circulationaha.117.030437.CrossRefPubMed

Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol. 2015;116(5):757–64. https://doi.org/10.1016/j.amjcard.2015.05.047.CrossRefPubMed

Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, et al. Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy. JAMA Cardiol. 2019;4:644–57. https://doi.org/10.1001/jamacardio.2019.1391.CrossRefPubMed

Ho CY, Link MS. Predicting the future in hypertrophic cardiomyopathy. Circulation. 2018;137(10):1024–6.CrossRef

10.

Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidimiology. 2010;21(1):128–38. https://doi.org/10.1097/EDE.0b013e3181c30fb2.CrossRef

11.

Maron BJ, Maron MS. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. Heart Rhythm. 2016;13(5):1155–65. https://doi.org/10.1016/j.hrthm.2015.12.048.CrossRefPubMed

12.

Wang N, Xie A, Tjahjono R, Tian DH, Phan S, Yan TD, et al. Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications. Ann Cardiothorac Surg. 2017;6(4):298–306. https://doi.org/10.21037/acs.2017.07.05.CrossRefPubMedPubMedCentral

13.

Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, et al. Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol. 2018;11(4):e005820.CrossRef

14.

Steyerberg EW, Calster BV, Pencina MJ. Performance measures for prediction models and markers: evaluation of predictions and classifications. Rev Esp Cardiol. 2011;64(9):788–94. https://doi.org/10.1016/j.rec.2011.05.004.CrossRefPubMed

15.

Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–72. https://doi.org/10.1002/sim.2929.CrossRef

16.

Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26(6):565–74. https://doi.org/10.1177/0272989X06295361.CrossRef

17.

You JJ, Woo A, Ko DT, Cameron DA, Mihailovic A, Krahn M. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Am Heart J. 2007;154(5):899–907. https://doi.org/10.1016/j.ahj.2007.06.026.CrossRefPubMed

18.

Goldenberg I, Moss AJ, Maron BJ, Dick AW, Zareba W. Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Ann Noninvasive Electrocardiol. 2005;10(4 Suppl):67–83. https://doi.org/10.1111/j.1542-474X.2005.00070.x.CrossRefPubMedPubMedCentral

19.

Meltzer MI. Introduction to health economics for physicians. Lancet. 2001;358(9286):993–8. https://doi.org/10.1016/s0140-6736(01)06107-4.CrossRefPubMed

20.

McKeown PP, Muir AR. Risk assessment in hypertrophic cardiomyopathy: contemporary guidelines hampered by insufficient evidence. Heart. 2013;99(8):511–3. https://doi.org/10.1136/heartjnl-2012-303363.CrossRefPubMedPubMedCentral

21.

Klopotowski M, Kukula K, Malek LA, Spiewak M, Polanska-Skrzypczyk M, Jamiolkowski J, et al. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy. J Cardiol. 2016;68(1):49–56. https://doi.org/10.1016/j.jjcc.2015.07.020.CrossRefPubMed

22.

Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484–95. https://doi.org/10.1161/circulationaha.113.007094.CrossRefPubMed

23.

Fluechter S, Kuschyk J, Wolpert C, Doesch C, Veltmann C, Haghi D, et al. Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2010;12:30. https://doi.org/10.1186/1532-429x-12-30.CrossRefPubMedPubMedCentral

24.

Prinz C, Schwarz M, Ilic I, Laser KT, Lehmann R, Prinz EM, et al. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy. Can J Cardiol. 2013;29(3):358–63. https://doi.org/10.1016/j.cjca.2012.05.004.CrossRefPubMed

25.

Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3(1):51–8. https://doi.org/10.1161/circheartfailure.109.854026.CrossRefPubMed

26.

Briasoulis A, Mallikethi-Reddy S, Palla M, Alesh I, Afonso L. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart. 2015;101(17):1406–11. https://doi.org/10.1136/heartjnl-2015-307682.CrossRefPubMed

27.

Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. J Am Coll Cardiol Img. 2016;9(12):1392–402. https://doi.org/10.1016/j.jcmg.2016.02.031.CrossRef

28.

Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118(15):1541–9.CrossRef

29.

Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol. 2017;69(7):761–73. https://doi.org/10.1016/j.jacc.2016.11.063.CrossRefPubMed

30.

Rowin EJ, Maron BJ, Chokshi A, Maron MS. Left ventricular apical aneurysm in hypertrophic cardiomyopathy as a risk factor for sudden death at any age. Pacing Clin Electrophysiol. 2018;41:1031–3. https://doi.org/10.1111/pace.13413.CrossRef

31.

Rowin EJ, Maron BJ, Abt P, Kiernan MS, Vest A, Costantino F, et al. Impact of advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2018;121(8):986–96. https://doi.org/10.1016/j.amjcard.2017.12.044.CrossRefPubMed

32.

Vriesendorp PA, Schinkel AF, Van Cleemput J, Willems R, Jordaens LJ, Theuns DA, et al. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. Am Heart J. 2013;166(3):496–502. https://doi.org/10.1016/j.ahj.2013.06.009.CrossRefPubMed

33.

Girolami F, Ho CY, Semsarian C, Baldi M, Will ML, Baldini K, et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol. 2010;55(14):1444–53. https://doi.org/10.1016/j.jacc.2009.11.062.CrossRefPubMed

34.

Maron BJ, Nishimura RA. Surgical septal myectomy versus alcohol septal ablation. Circulation. 2014;130(18):1617–24.CrossRef

35.

Cuoco FA, Spencer WH, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL, et al. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52(21):1718–23. https://doi.org/10.1016/j.jacc.2008.07.061.CrossRefPubMed

36.

Jensen MK, Prinz C, Horstkotte D, van Buuren F, Bitter T, Faber L, et al. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart. 2013;99(14):1012–7. https://doi.org/10.1136/heartjnl-2012-303339.CrossRefPubMed

37.

Veselka J, Tomasov P, Zemanek D. Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years. Can J Cardiol. 2011;27(6):763–7. https://doi.org/10.1016/j.cjca.2011.09.001.CrossRefPubMed

38.

Vriesendorp PA, Liebregts M, Steggerda RC, Schinkel AFL, Willems R, ten Cate FJ, et al. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC: Heart Failure. 2014;2(6):630–6. https://doi.org/10.1016/j.jchf.2014.06.012.CrossRefPubMed

39.

ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail. 2010;3(3):362–9. https://doi.org/10.1161/circheartfailure.109.862359.CrossRefPubMed

40.

Noseworthy PA, Rosenberg MA, Fifer MA, Palacios IF, Lowry PA, Ruskin JN, et al. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2009;104(1):128–32. https://doi.org/10.1016/j.amjcard.2009.02.056.CrossRefPubMed

41.

Saumarez RC, Pytkowski M, Sterlinski M, Bourke JP, Clague JR, Cobbe SM, et al. Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J. 2008;29(13):1653–61. https://doi.org/10.1093/eurheartj/ehn111.CrossRefPubMed

42.

Maron BJ, Rowin EJ, Casey SA, Lesser JR, Garberich RF, McGriff DM, et al. Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies. Circulation. 2016;133(1):62–73. https://doi.org/10.1161/circulationaha.115.017633.CrossRefPubMed

43.

Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA 3rd, et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61(14):1527–35. https://doi.org/10.1016/j.jacc.2013.01.037.CrossRefPubMed

44.

Spirito P, Autore C, Formisano F, Assenza GE, Biagini E, Haas TS, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014;113(9):1550–5. https://doi.org/10.1016/j.amjcard.2014.01.435.CrossRefPubMed

45.

Maron BJ, Maron MS, Lesser JR, Hauser RG, Haas TS, Harrigan CJ, et al. Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Am J Cardiol. 2008;101(4):544–7. https://doi.org/10.1016/j.amjcard.2007.09.101.CrossRefPubMed

46.

Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol. 2015;65(18):1915–28. https://doi.org/10.1016/j.jacc.2015.02.061.CrossRefPubMed

47.

Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013;127(5):585–93. https://doi.org/10.1161/circulationaha.112.136085.CrossRefPubMed

Titel: Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists
verfasst von: Arya Aminorroaya
Ali Vasheghani-Farahani
Farzad Masoudkabir
Pegah Roayaei
Publikationsdatum: 25.07.2020
Verlag: Springer US
Erschienen in: Journal of Interventional Cardiac Electrophysiology / Ausgabe 1/2021
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI: https://doi.org/10.1007/s10840-020-00837-4

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists

Abstract

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Second-generation cryoballoon vs. contact-force sensing radiofrequency catheter ablation in atrial fibrillation: a meta-analysis of randomized controlled trials

Outcome of ACHD patients with non-inducible versus inducible IART undergoing cavo-tricuspid isthmus ablation: the role of empiric ablation

How to avoid unnecessary RF applications in cavo-tricuspid isthmus: common atrial flutter ablation using 8-mm-tip mini-electrode-equipped catheter

Dynamic changes in the signal-averaged electrocardiogram are associated with the long-term outcomes after ablation of ischemic ventricular tachycardia

Tachycardia cycle length alternans in orthodromic reciprocating tachycardia due to mutually dependent dual AV node physiology and retrograde supernormal conduction

Transhepatic right vein access for radiofrequency ablation of atrioventricular nodal reentry tachycardia in a patient with infrarenal vena cava agenesis

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie